Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine.
Cancer Lett
; 263(2): 291-301, 2008 May 18.
Article
en En
| MEDLINE
| ID: mdl-18291576
ABSTRACT
BACKGROUND:
C-IRIV/PTR-4 is a novel anticancer vaccine construct composed of immune-reconstituted influenza virosomes (IRIV) assembled with the PTH-rP derived peptide (PTR)-4, a synthetic CTL epitope with HLA-A(*)02.01 amino acid binding motifs. This peptide is able to generate a human PTH-rP specific CTL response with anti-tumor activity in vitro and in mice. MATERIALS ANDMETHODS:
We have investigated the immunological and preventive anti-tumor activity of C-IRIV/PTR-4 compared with the soluble PTR-4 peptide, in HHD mice inoculated with autologous PTH-rP+ tumor cells.RESULTS:
Peptide vaccination with either a soluble and an IRIV formulation showed similar immunological activity and the ability to purge the tumor tissue of tumor cell clones able to produce the target antigen (PTR-rP). The most efficient protection from tumor growth was however observed in animals vaccinated with C-IRIV/PTR-4 in which an additional IRIV related anti-angiogenetic effect was detected in the tumor tissue.CONCLUSIONS:
These results confirm the immunological activity of PTR-4 vaccination and suggest a more efficacious therapeutic potential of C-IRIV/PTR-4 against bone metastases and malignancies like breast, prostate and lung which very often over-express PTH-rP.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Virus de la Influenza A
/
Vacunas contra el Cáncer
/
Vacunas de Virosoma
/
Proteína Relacionada con la Hormona Paratiroidea
/
Neovascularización Patológica
Tipo de estudio:
Evaluation_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Cancer Lett
Año:
2008
Tipo del documento:
Article
País de afiliación:
Italia